1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Fagron N.V.
  6. News
  7. Summary
    FAGR   BE0003874915


Real-time Quote. Real-time Euronext Bruxelles - 05/23 07:36:41 am
16.23 EUR   +0.31%
05/16FAGRON N.V. : Ex-dividend day for final dividend
05/09Fagron shareholders approve all voting items AGM and EGM
05/09Fagron NV Approves Dividend for the Fiscal Year 2021, Payable on 18 May 2022
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Fagron N : publishes 2022 ESG targets

01/13/2022 | 04:01am EDT

Nazareth (Belgium)/Rotterdam (The Netherlands), 13 January 2022 - 9:30AM CET

Fagron publishes 2022 ESG targets

Corporate social responsibility is at the heart of Fagron's operations and strategy. Fagron's products and services contribute every day to improving the health of people worldwide. Fagron strives to:

  • reduce its impact on the environment;
  • provide products that meet all relevant quality and safety standards;
  • provide benefit to its people;
  • take responsibility in the supply chain; and
  • give back to the communities in which Fagron operates.

To give concrete expression to this aspiration, Fagron is publishing its ESG objectives for 2022.

In addition to the previously defined targets for reducing the greenhouse gas intensity of Fagron's operations, Fagron also sets itself the objective in its 2022 ESG plan, among others, to purchase 50% of its electricity from renewable sources by 2025 and to separate waste at all its locations. In terms of gender equality, Fagron aims not only to have a 50/50 gender distribution of all its staff, but by 2025 also at management level. Furthermore, Fagron wants at least 75% (in purchasing value) of its suppliers to have accepted the Fagron Business Partner Code of Conduct by 2025. The full 2022 ESG plan of Fagron, including all targets can be read on our website.

Rafael Padilla, CEO of Fagron: "Corporate social responsibility is at the heart of what we do: by personalizing medicine, they become accessible to even more people. In 2021 we presented our ESG strategy and reported extensively on our social responsibility for the first time in our 2020 annual report. Since then, we have made some important steps, such as a significant reduction in the greenhouse gas intensity of our operations (scope 1, 2 and business travel) and an increase in the number of annual performance and development reviews of our employees to 85%. However, we must continue to develop ourselves. Fagron is thus constantly adapting its ESG strategy in response to developments in the ESG field, trends in the sector and regions where we operate, and the input we receive from our stakeholders. I am proud that we have again set ourselves challenging targets for 2022 to make our contribution to a better world."

Fagron endorses all 17 Sustainable Development Goals (SDGs) defined by the United Nations in 2015. Based on the defined sustainability strategy, Fagron has selected five categories where it actively focuses and where it believes it can make the highest contribution: environment, our people, supply chain responsibility, giving back and good governance.

Further information

About Fagron
Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in 35 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. Fagron's operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Please open the link below for the press release:
Fagron publishes 2022 ESG targets


Fagron NV published this content on 13 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2022 09:00:09 UTC.

© Publicnow 2022
All news about FAGRON N.V.
05/16FAGRON N.V. : Ex-dividend day for final dividend
05/09Fagron shareholders approve all voting items AGM and EGM
05/09Fagron NV Approves Dividend for the Fiscal Year 2021, Payable on 18 May 2022
05/09Fagron NV Announces New Executive Appointment
05/09FAGRON N.V. : Proxy Statments
05/02Disclosure of received notification from NN Group N.V.
05/02Disclosure of received notification from NN Group N.V.
04/29Fagron acquires majority share of Fraunhofer IPMS' spin-off HiperScan
04/27Fagron NV acquired unknown minority stake in HiperScan GmbH from High-Tech GrÜNderfonds..
04/21FAGRON N : presentation Kempen Life Sciences Conference Amsterdam (20 April 2022)
More news
Sales 2022 645 M 680 M 680 M
Net income 2022 69,0 M 72,8 M 72,8 M
Net Debt 2022 266 M 281 M 281 M
P/E ratio 2022 17,2x
Yield 2022 1,17%
Capitalization 1 179 M 1 244 M 1 244 M
EV / Sales 2022 2,24x
EV / Sales 2023 1,90x
Nbr of Employees 2 846
Free-Float -
Duration : Period :
Fagron N.V. Technical Analysis Chart | FAGR | BE0003874915 | MarketScreener
Technical analysis trends FAGRON N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Last Close Price 16,18 €
Average target price 21,00 €
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Rafael Padilla Papaceit Chief Executive Officer & Executive Director
Karin de Jong Chief Financial Officer & Executive Director
Koen Hoffman Chairman
Giulia van Waeyenberge Independent Director
Hein Valere Maria Deprez Independent Director
Sector and Competitors
1st jan.Capi. (M$)
FAGRON N.V.9.32%1 244
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707